Key points are not available for this paper at this time.
In high AMR burden settings with blood culture infrastructure supporting fast turnaround times, a molecular test could improve health outcomes of bloodstream infection. Impact is limited by delayed turnaround times and the effectiveness of empiric therapy. Molecular diagnostics implemented at 100 or less can generate healthcare-system cost savings, supporting their adoption to improve health outcomes and reduce AMR while remaining cost-neutral.
Chevalier et al. (Fri,) studied this question.